Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
Rhea-AI Summary
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on novel mechanisms for prevalent, underserved diseases, will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 1:35 p.m. ET.
A live webcast and 30-day replay will be accessible via the events and presentations section of the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – NMRA
In the May 13 session, NMRA declined 6.32%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | -16.7% | Q1 2026 results and business update with cash runway into Q3 2027. |
| Apr 06 | Conference participation | Neutral | +6.0% | Announcement of Needham virtual healthcare conference fireside chat webcast. |
| Mar 30 | FY 2025 earnings | Positive | -17.2% | Q4 and full-year 2025 results with Phase 3 and pipeline milestones outlined. |
| Mar 16 | Earnings date notice | Neutral | +1.0% | Scheduling notice for Q4 and FY 2025 results call and webcast details. |
| Feb 04 | Conference participation | Neutral | -1.0% | Participation in Guggenheim biotech summit with webcast and replay access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and business updates have recently seen sharp negative reactions, while conference participation headlines have produced relatively modest, mixed moves.
Over the last few months, Neumora has reported multiple earnings and business updates alongside a steady cadence of conference appearances. Q4 2025 and Q1 2026 results, both highlighting cash runway into Q3 2027 and progress in KOASTAL-2/-3 and other programs, were followed by double‑digit share declines. By contrast, prior conference participation news (Needham in April 2026 and Guggenheim in February 2026) saw modest price changes. Today’s RBC conference participation fits that non-fundamental, visibility-focused pattern rather than marking a new financial or clinical inflection.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 1:35 p.m. ET.
A live webcast of the fireside chat will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
